Revenue $9.76B, up 13.7% on a year earlier. Diabetes revenue $843.00M, up 16.9%. Neuromodulation Revenue $539.00M, up 6.9%. Diluted EPS $1.14 against $0.81.
| Q1 FY27 | Q4 FY26 | Q1 FY26 | Year over year | |
|---|---|---|---|---|
| Revenue | $9.76B | $9.81B | $8.58B | +13.7% |
| Operating income | $1.76B | $1.87B | $1.45B | +22.1% |
| Net income | $1.47B | $1.24B | $1.04B | +41.3% |
| Diluted EPS | $1.14 | $0.97 | $0.81 | |
| Operating cash flow | $1.79B | $2.57B | $1.09B | +64.8% |
| Capital expenditures | -$503.00M | -$488.00M | -$504.00M | |
| Free cash flow | $1.29B | $2.08B | $584.00M | +120.9% |
| Dividend per share | $0.71 | $0.71 | $0.71 |
| Q1 FY27 | Q1 FY26 | Year over year | |
|---|---|---|---|
| Diabetes revenue | $843.00M | $721.00M | +16.9% |
| Neuromodulation Revenue | $539.00M | $504.00M | +6.9% |
| Cardiovascular Portfolio revenue | $3.93B | $3.29B | +19.5% |
| Cranial & Spinal Technologies revenue | $1.36B | $1.21B | +12.7% |
| Surgical & Endoscopy revenue | $1.74B | $1.61B | +7.9% |
| U.S. Revenue | $4.91B | $4.22B | +16.1% |
| Medical Surgical Portfolio revenue | $2.28B | $2.08B | +9.4% |
| Neuroscience Portfolio revenue | $2.68B | $2.42B | +10.8% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Medtronic (MDT) Q1 FY27 earnings: results and KPIs”, stockatlas.com/companies/MDT/earnings/2027-q1/, data as of 3 November 2026. Links to this page are welcome.
